Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multiple Dose, Dose Escalation Trial of AEB1102 (Co-Arg1-PEG) in Patients With Advanced Solid Tumors

NCT02561234 is registered in ClinicalTrials.gov with Immedica Pharma AB as lead sponsor.

NCT NCT02561234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02561234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multiple Dose, Dose Escalation Trial of AEB1102 (Co-Arg1-PEG) in Patients With Advanced Solid Tumors
Lead sponsor
Immedica Pharma AB
Phase
Phase 1
Overall status
Completed
Start date
October 22, 2015
Completion date
May 28, 2019
Enrollment
76 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancers